Kalvista Pharmaceuticals (NASDAQ:KALV) is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. The company's primary projects are centered around treatments for hereditary angioedema (HAE) and diabetic macular edema (DME), two conditions that significantly impact patients' quality of life. With a mission to provide novel therapies that improve clinical outcomes, Kalvista is dedicated to advancing its portfolio through rigorous scientific research and clinical trials. The company's strategy emphasizes collaboration, innovation, and speed to market, aiming to bring transformative treatments to patients who need them the most.